Brief: Cytomx Therapeutics Announces Positive Initial Phase 1A Dose Escalation Data For Monotherapy Cx-904
08/05/2024 21:42
May 8 (Reuters) - CytomX Therapeutics Inc CTMX.O :
* CYTOMX THERAPEUTICS ANNOUNCES POSITIVE INITIAL PHASE 1A
DOSE
ESCALATION DATA FOR MONOTHERAPY CX-904 (EGFRXCD3 PROBODY® T-CELL
ENGAGER)
* CYTOMX THERAPEUTICS INC - EXPECTS TO PROVIDE AN ADDITIONAL
PHASE
1A DOSE ESCALATION UPDATE BY END OF 2024
* CYTOMX THERAPEUTICS- PRELIMINARY PHARMACOKINETIC &
PHARMACODYNAMIC ANALYSES ARE SUPPORTIVE OF PROBODY(®) T-CELL
ENGAGER PLATFORM MECHANISM OF ACTION
Source text for Eikon: ID:nGNX33n3NK
Further company coverage: CTMX.O
Recent news on CytomX Therapeutics
See all newsCytomX Q2 revenue misses, partly hurt by lower research activities in the Astellas collaboration
CytomX Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Cytomx Therapeutics Announces Appointment Of Charles Fuchs, M.D., M.P.H., To The Board Of Directors
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway